Menu Search
Equities

Diagnos Laboratorium Utama PT Tbk

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DGNS:JKT

Diagnos Laboratorium Utama PT Tbk

Actions
Health CareMedical Equipment and Services
  • Price (IDR)304.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.60m
  • 1 Year change+69.83%
  • Beta0.1001
Data delayed at least 10 minutes, as of Feb 18 2026 09:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Diagnos Laboratorium Utama Tbk is an Indonesia-based company engaged in providing health services using laboratories. Its activities also include private clinical activities. Its products and services include clinical pathology laboratories, anatomical pathology laboratories, genomics laboratories, homecare health services, and corporate health services. The clinical pathology laboratory provides examinations for hematology, hemostasis, clinical chemistry, urinalysis, biomolecular tests, and more. The anatomical pathology laboratory offers examination services for tissues and body fluids. The genomics laboratory provides genetic examination services to confirm suspected genetic conditions and determine the possibility of a person acquiring or inheriting a genetic disorder. The homecare health services offer health checks that can be conducted at home, eliminating the need to visit the laboratory. The corporate health services offer medical check-ups for corporate customers.

  • Revenue in IDR (TTM)--
  • Net income in IDR--
  • Incorporated--
  • Employees111.00
  • Location
    Diagnos Laboratorium Utama PT TbkJakartalaboratoryJl. Teuku Cik Ditiro No.28 CentralJAKARTA PUSAT IndonesiaIDN
  • Phone+62 2 131931883
  • Websitehttps://diagnos.co.id/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.